Pegtarazimod (RLS-0071)
Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
Phase 2Active
Key Facts
Indication
Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
Phase
Phase 2
Status
Active
Company
About ReAlta Life Sciences
ReAlta Life Sciences is a private, pre-revenue biotech founded in 2018 and based in Norfolk, Virginia, USA. The company is advancing pegtarazimod, a dual-targeting anti-inflammatory peptide, with a lead Phase 2 program in neonatal HIE, a devastating condition with no approved disease-modifying therapies. Its platform aims to broadly address inflammatory diseases by targeting upstream drivers (complement and neutrophils), supported by an experienced leadership team including the original scientific discoverers. ReAlta represents a high-risk, high-reward opportunity in the niche but critical area of neonatal neurology and inflammation.
View full company profileTherapeutic Areas
Other Neonatal Hypoxic-Ischemic Encephalopathy (HIE) Drugs
| Drug | Company | Phase |
|---|---|---|
| THDG3 | DeckTherapeutics | Pre-clinical |